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ABSTRACT
Background
Interventions designed to narrow the gap between research findings and clinical practice
may be effective, but also costly. Economic evaluations are necessary to judge whether such
interventions are worth the effort. We have evaluated the economic effects of a tailored
intervention to support the implementation of guidelines for the use of antihypertensive and
cholesterol-lowering drugs. The tailored intervention was evaluated in a randomized trial, and
was shown to significantly increase the use of thiazides for patients started on antihypertensive
medication, but had little or no impact on other outcomes. The increased use of thiazides was
not expected to have an impact on health outcomes.
Methods and Findings
We performed cost-minimization and cost-effectiveness analyses on data from a randomized
trial involving 146 general practices from two geographical areas in Norway. Each practice was
randomized to either the tailored intervention (70 practices; 257 physicians) or control group
(69 practices; 244 physicians). Only patients that were being started on antihypertensive
medication were included in the analyses. A multifaceted intervention was tailored to address
identified barriers to change. Key components were an educational outreach visit with audit
and feedback, and computerized reminders. Pharmacists conducted the visits. A cost-
minimization framework was adopted, where the costs of intervention were set against the
reduced treatment costs (principally due to increased use of thiazides rather than more
expensive medication). The cost-effectiveness of the intervention was estimated as the cost per
additional patient being started on thiazides. The net annual cost (cost minimization) in our
study population was US$53,395, corresponding to US$763 per practice. The cost per
additional patient started on thiazides (cost-effectiveness) was US$454. The net annual savings
in a national program was modeled to be US$761,998, or US$540 per practice after 2 y. In this
scenario the savings exceeded the costs in all but two of the sensitivity analyses we conducted,
and the cost-effectiveness was estimated to be US$183.
Conclusions
We found a significant shift in prescribing of antihypertensive drugs towards the use of
thiazides in our trial. A major reason to promote the use of thiazides is their lower price
compared to other drugs. The cost of the intervention was more than twice the savings within
the time frame of our study. However, we predict modest savings over a 2-y period.
The Editors’ Summary of this article follows the references.
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Implementing high-quality clinical practice guidelines may
be a way of improving clinical practice. However, the effect of
implementation strategies is usually modest, and more
effective interventions, such as educational outreach visits,
tend to be more costly [1]. There are numerous trials of
quality improvement strategies, but comprehensive cost–
beneﬁt or cost-effectiveness analyses are scarce. The authors
of a recent systematic review of guideline implementation
strategies found that ‘‘relatively few studies considered any
costs other than those of treatment and its consequences’’ [2].
We have conducted a rigorous evaluation of a tailored
intervention designed to improve prescribing of antihyper-
tensive and cholesterol-lowering drugs in primary practice
(Figure 1) [3]. The intervention was multifaceted, and
included (1) an educational outreach visit to clinics, during
which guidelines were presented and discussed, (2) an audit
and feedback on current adherence to guidelines and
recommendations, and (3) a system providing computerized
reminders to the physicians during patient consultations. The
effectiveness of this multifaceted intervention was evaluated
in a randomized controlled trial, in which the control
intervention was passive dissemination of guidelines through
a national medical journal [3]. The main outcomes analyzed
in the trial were the following: (1) the proportion of
prescriptions of thiazide-type diuretics to patients being
prescribed antihypertensive drugs for the ﬁrst time, for
primary prevention of cardiovascular disease, (2) the pro-
portion of patients for whom the level of cardiovascular risk
had been estimated among all those started on antihyperten-
sive or cholesterol-lowering treatment for primary preven-
tion, and (3) the proportion of patients with a recorded level
of cholesterol (total or low-density lipoprotein) or blood
pressure satisfying the speciﬁed treatment goals among all
patients on the corresponding treatment for at least 3 mo.
For cholesterol we decided to also include patients on
secondary prevention therapy since the treatment goals are
similar.
The intervention resulted in increased prescribing of
thiazides, but no signiﬁcant changes in the two other main
outcomes. With regards to health outcomes, the choice of
antihypertensive drug has limited impact [4,5], and was
disregarded in our analyses. Consequently, the primary
question was whether the savings on drug costs were greater
than the costs of the intervention, given that the cost of
thiazides is much lower than that of other antihypertensive
drugs. Thus, we conducted a cost-minimization analysis
comparing costs and effects of two strategies: (1) our
multifaceted intervention and (2) usual care. We were also
interested in knowing the costs incurred relative to the
achieved changes in clinical practice, a form of cost-
effectiveness analysis.
Methods
Data collection for the economic analysis was planned
before the trial was conducted. The study protocol is available
via the Norwegian Knowledge Centre for Health Services
Web site [6] and as Protocol S1.
We conducted our analyses from the perspective of the
health system, i.e., those who pay for health care, since
implementing these clinical practice guidelines mainly had
economic implications for the funders of health care. In
Norway most health care is paid for by the government and,
to a minor extent, through user fees.
Effects/Benefits
Dissemination and implementation of guideline. There may
be beneﬁts resulting directly from the implementation
activities, such as increased clinical knowledge or job
satisfaction among the physicians, but we have no empirical
Figure 1. Design of Cluster-Randomized Trial
DOI: 10.1371/journal.pmed.0030216.g001
PLoS Medicine | www.plosmedicine.org June 2006 | Volume 3 | Issue 6 | e216 0793
RaPP Trial: Economic Evaluationdata or other sound basis for estimating these effects and
therefore did not include them in the analysis.
Changes in clinical practice as a result of guideline
implementation. The trial results demonstrated a statistically
signiﬁcant effect only on prescribing (Table 1). For other
outcomes we assume an absence of effect since the point
estimates for the relative risks were close to one (Table 1).
Costs
We included all identiﬁable costs related to the implemen-
tation of our intervention. The cost of guideline development
was identical for both arms of the trial. Our analysis therefore
focused on the incremental costs and savings of implementa-
tion beyond guideline development.
There were both nonrecurring and recurring costs related
to dissemination and implementation of the guideline.
Nonrecurring costs included development of software and
training of outreach visitors. Recurring costs included
printed materials, travels to outreach visits, salaries for the
pharmacists conducting outreach visits, salary for the person
making appointments for outreach visits, costs for other
administrative tasks, e.g., follow-up of practices and coordi-
nation of outreach visits, and the opportunity cost of
physicians’ time during outreach visits. The primary cost
consequence of changes in clinical practice resulting from
guideline implementation was the recurring costs of drug
expenditures. Data on costs and effects were collected from
the 73 practices in the experimental arm of the trial, with the
exception of three practices for which data collection was not
possible. Outcome data, including drug costs, were also
collected from the control practices.
The data sources we used for estimating resource usage are
shown in Table 2.
Table 1. Main Results from Intervention Trial
Outcome Intervention Group Control Group Percentage
Difference
Intracluster
Correlation
Coefficient
a
Relative Risk
a
(95% Confidence
Interval)
p-Value
b
Baseline Follow-Up Percentage
Change
Baseline Follow-Up Percentage
Change
Prescribing of
thiazides for
hypertension
b
(number of
patients)
161/2,784
(5.8%)
378/2,184
(17.3%)
11.5 209/2,365
(8.8%)
218/1,968
(11.1%)
2.2 9.3 0.087 1.94 (1.49; 2.49) ,0.0001
Cardiovascular
risk assessment
done (number
of patients)
— 147/854
(17.2%)
— — 112/768
(14.6%)
— 2.6 0.39 1.04 (0.60; 1.71) 0.90
Treatment
goal achieved
c
(number of
patients)
4,669/15,914
(29.3%)
5,502/17,213
(32.0%)
2.6 5,174/15,411
(33.6%)
6,056/16,593
(36.5%)
2.9 0.3 0.026 0.98 (0.93; 1.02) 0.33
aAdjusted for baseline differences and clustering effects (generalized estimation equation).
bFewer data on exclusion criteria were available for the baseline period, explaining the higher number of prescriptions during the baseline period than during follow-up.
c Recommended treatment goal for blood pressure, ,140/90 mm Hg; for lipids, total cholesterol , 5 mmol/l (190 mg/dl) and/or low-densitylipoprotein cholesterol , 3 mmol/l (115 mg/dl).
DOI: 10.1371/journal.pmed.0030216.t001
Table 2. Input Variables in Economic Analysis
Variable Data Sources (in Natural Units) Data Sources (in Monetary Units)
Development of software Invoices, estimates of time spent Invoices, salary payments
Training of outreach visitors Estimate of time spent, invoices Salary payments
Printed materials Invoice Invoice
Travels costs Record of travel days, estimate of travel distances Travel invoices
Cost of pharmacists doing outreach Record of number of visits and days spent on visits Salary payments
Administrative costs, e.g., making
appointments for outreach visits
Records and estimates of time expenditure Salary payments, standard estimates for
overheads, office rental figures
Opportunity cost of physician time Record of length of outreach visit and
number of physicians present
Standard tariff for interdisciplinary meetings
Technical support Invoices Invoices
Drug expenditure Medical records of prescribing Drug prices according to Felleskatalog 2003 [14]
Number of consultations per patient Medical records Standard tariff for consultation, average
wage rates (patients), and tax rates
Laboratory test (potassium) — Standard tariff
DOI: 10.1371/journal.pmed.0030216.t002
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the outreach visit took place. The primary analysis is based on
these data and assumes that all costs and all beneﬁts occur
within the same year; thus, we can disregard discounting.
However, discounting was included in the analyses in which
effects were modeled beyond 1 y. We used a discounting rate
of 4%, in accordance with guidelines from the Norwegian
Ministry of Finance. Value added tax was excluded from the
cost ﬁgures in the analyses. Salary costs included payroll
taxes, social costs, and a 40% institutional overhead.
All ﬁgures are expressed in 2002 United States dollars, using
the 2002 average exchange rate from Norwegian kroner [7].
Analysis
Cost minimization. For the cost-minimization analysis we
included all costs related to the intervention, including drug
costs (Protocol S2, Equation 1). For the usual-care group we
assumed no intervention costs.
We estimated drug costs by multiplying the total number of
prescriptions of antihypertensives to patients started on
treatment in the intervention group during the study period
by the difference in cost per prescription between the two
groups (Protocol S2, Equation 2). We adjusted for baseline
differences (Protocol S2, Equation 3).
Cost-effectiveness. We deﬁned cost-effectiveness as the cost
incurred per additional patient started on a thiazide rather
than another antihypertensive drug; i.e., an incremental cost-
effectiveness ratio of intervention versus usual care (Protocol
S3, Equation 1).
We did not include savings resulting from changes in
prescribing patterns in the cost-effectiveness analysis since
our objectivewas toproduce an estimate with relevance across
interventions that target prescribing habits, independent of
whether a change leads to higher or lower drug expenditures.
The number of patients started on thiazides because of the
intervention was calculated by multiplying the absolute
between-group difference in proportion of patients started
on thiazides by the total number of patients started on
antihypertensive treatment in the intervention group (Pro-
tocol S3, Equation 2). We adjusted for baseline differences
between the groups (Protocol S3, Equation 3).
Assumptions
We assumed there were no effects on health outcomes or
on the use of health services for two reasons. Firstly, the
association between choice of antihypertensive drug and
health outcomes is marginal [4,5]. Secondly, the average
number of consultations per patient started on antihyper-
tensive therapy was the same (4.0) in both groups in the study.
We did not have access to the number of tablets per
prescription. Based on data we recently collected in a similar
population of practices and patients [8], we assumed that one
prescription represented a standard package of 100 tablets (or
the available package size closest to this), which was dispensed
twice. We assumed that the strength of the prescribed tablets
corresponded to one deﬁned daily dosage [9].
We excluded costs related to patient time since we found it
unlikely that the intervention had an effect on this.
Sensitivity Analysis
We performed univariate sensitivity analyses with adjusted
values for all variables we believed could impact on our
ﬁndings.
Scaling Up to Nationwide Implementation
We used our ﬁndings in a model to estimate the economic
consequences of scaling up the intervention to a national
outreach program. The model was based on the following
prespeciﬁed assumptions: (1) 90% of all practices in Norway
covered (using a total number of practices of 1,567 [A.
Taraldset, Norwegian Medical Association, personal commu-
nication]), (2) same effect on prescribing as observed in the
trial, (3) same pattern of prescribing as in the study
population, and (4) higher travel costs than in the trial due
to longer distances to cover.
In order to produce a best estimate for the cost of a
national program, we added the following assumptions:
software development costs same as in trial, salary for
pharmacists set to average salary wage among pharmacy
pharmacists in Norway, i.e., about 50% higher than
pharmacist salaries in the trial [10], each outreach visitor
covers 200 practices per year, opportunity costs of physicians
included, average price of thiazides and non-thiazides
unchanged from trial, effect on drug costs sustained for 2 y
(i.e., the patients started on antihypertensives during the ﬁrst
year continue taking the same drugs during the full second
year, and prescribing of antihypertensives for new patients in
year two follows the same pattern as in year one), one
potassium test ordered per additional patient started on
thiazides (US$3.60 per test), and travel costs doubled
compared to trial.
Finally, we also tested the robustness of our national
program model by adjusting the values of most variables in
univariate sensitivity analyses.
Results
The estimated costs for the various classes of antihyper-
tensive drugs are shown in Table 3, including the total
number of prescriptions (5,191 in intervention group) and
costs per prescription (net change: US$7.47). Thus, savings on
drugs were estimated to be US$38,773 for the 70 practices in
the intervention group over 1 y.
All costs and savings related to the intervention are
presented in Table 4. The net cost (cost minimization) of
implementing the intervention in our study population was
US$53,395, corresponding to US$763 per practice.
The trial results demonstrated an effect of the intervention
on the prescribing of thiazides, with an absolute increase of
9.3% (Table 1, adjusted for baseline differences). The total
number of patients started on medication in the intervention
group was 2,184; 203 patients (9.3% of 2,184) were started on
thiazides rather than another drug because of the interven-
tion. The cost of the intervention, excluding savings on drugs,
added up to US$92,168. Consequently, the cost-effectiveness
of the intervention, i.e., the cost per additional patient
started on thiazides, was US$454.
Sensitivity Analyses
Adjusting the assumptions in our main analysis had an
impact on the estimated cost of the intervention, but the
costs remained higher than the savings in all the univariate
sensitivity analyses we conducted, except when we assumed
that the effect of the intervention would be sustained for a
second year (Table 5).
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In our model for estimating the economic impact of a
national outreach program, the savings exceeded the costs,
largely because of our assumption of the effect being
sustained over 2 y (Table 6). The total annual savings
amounted to US$761,998, or US$540 per practice. The
savings also exceeded the costs in all but two of the univariate
sensitivity analyses we conducted on this model (Table 7). The
cost-effectiveness was estimated to be US$183 per additional
patient started on a thiazide.
Discussion
We found a considerable shift in the prescribing of
antihypertensive drugs towards the use of thiazides in our
trial. In our economic analysis of the trial data we found that
reduced drug expenditures due to increased use of thiazides
did not outweigh the costs of the intervention. However,
assuming that the effect is sustained for a second year, the
picture changes and the intervention can be expected to lead
to savings. We predict modest savings within 2 y if the
intervention is implemented in a national program.
The key issue in determining the cost-saving potential of
the intervention is whether the intervention effect will be
sustained beyond a year, which was the duration of the trial.
There are two good reasons to believe that this will be the
case. Firstly, it is reasonable to believe that most patients who
start using thiazides will continue to use these drugs rather
than the more expensive alternatives, although many patients
will be started on additional drugs regardless of the ﬁrst drug
Table 4. Costs Related to the Intervention
Item Total Costs in Study Population Costs per Practice (Standard Deviation)
Natural Units Monetary
Units
(in US$)
Natural Units Monetary
Units
(in US$)
Software development 440 h 25,617 6.3 h 366
Training of outreach visitors 410 h 17,179 5.6 h 245
Printed materials 500 guidelines 4,085 7.1 guidelines 58
Travel costs
a 68 visits, average 84 km 7,643 1 visit, average 84 km (58) 109 (51)
Salary of pharmacists doing outreach 503 h 20,079 7.2 h 287
Administration costs 60 h 1,984 0.9 h, office rent, overheads 28
Physician opportunity cost 88 h 8,730 1.3 h (0.8) 125 (53)
Technical support 91 h 6,851 1.3 h (4.7) 98 (192)
Drug costs 9.3% absolute increase in proportion
of patients started on thiazides
38,773 9.3% absolute increase in proportion of
patients started on thiazides
554
Total 53,395 763
aFor two of the 70 practices in the analysis no outreach visit was conducted.
DOI: 10.1371/journal.pmed.0030216.t004
Table 3. Number of Prescriptions and Drug Costs during Study and Baseline Periods
Period Drug Class
a Intervention Group Control Group
N (%) Cost (US$) Cost per
Prescription
(US$)
N (%) Cost (US$) Cost per
Prescription
(US$)
Baseline (one year
before outreach visit)
b C02 178 (3) 23,931 134.45 172 (3) 23,664 137.58
C03A/C03E 321 (5) 5,084 15.84 370 (6) 5,794 15.66
C07 1,474 (21) 97,798 66.35 1,233 (20) 85,975 69.73
C08 1,016 (15) 112,641 110.87 868 (14) 97,042 111.80
C09 3,956 (57) 544,555 137.65 3,435 (57) 477,573 139.03
Total 6,945 (100) 784,009 112.89 6,078 (100) 690,048 113.53
Study (one year
after outreach visit) C02 145 (3) 20,029 138.13 113 (2) 15,360 135.93
C03A/C03E 697 (13) 11,515 16.52 409 (9) 6,795 16.61
C07 1,215 (23) 88,429 72.78 930 (20) 68,968 74.16
C08 574 (11) 63,747 111.06 552 (12) 61,352 111.15
C09 2,560 (49) 353,901 138.24 2,695 (57) 372,314 138.15
Total 5,191 (100) 537,621 103.57 4,699 (100) 524,789 111.68
aCO2 are predominantly alpha-blocking agents; C03A/C03E are thiazides; C07 are beta-blocking agents; C08 are calcium channel blockers; C09 are ACE inhibitors and angiotensin
receptor blockers.
bOne year prior to intervention period. Fewer data on exclusion criteria were available for the baseline period, explaining the higher number of prescriptions during the baseline period
than during follow-up.
DOI: 10.1371/journal.pmed.0030216.t003
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Secondly, it is likely that the intervention will continue to
inﬂuence physicians’ choice of antihypertensive medication
for new patients beyond the ﬁrst year after the outreach visit
took place. In the trial, the rate of thiazide prescribing to new
patients was stable throughout the study period in the
intervention group, with the effect showing no sign of waning
over time.
Whether it is reasonable to assume that the intervention
effect will be sustained beyond 2 y is less certain. Firstly, the
pharmaceutical market is dynamic, with prices constantly
changing and the regular introduction of new products.
Secondly, countermeasures from pharmaceutical companies
may be anticipated if health authorities launch national
outreachprogramsaimedtoinﬂuencephysicians’ prescribing.
There are few other economic analyses with which we can
compare our results. Whether a cost of US$454 for changing
a prescribing decision is a good or bad result is unclear. The
intervention also targeted other behaviors, such as physicians’
use of risk assessment tools, and had little or no impact on
these. Thus, for these behaviors the intervention would be
more costly but no more effective, i.e., it would represent an
inefﬁcient use of resources.
In light of these results, policy-makers need to consider
alternative strategies if they wish to inﬂuence prescribing
more cost-effectively. Recently, authorities in Norway made
thiazides mandatory as ﬁrst-choice medication if patients
were to have drug costs reimbursed through the national
health insurance system. The effectiveness of this strategy is
under evaluation. Another alternative is establishing a
maximum level of reimbursement for a group of drugs
assumed to be therapeutically equivalent (reference pricing).
This strategy has been thoroughly evaluated in British
Columbia, Canada, for one class of antihypertensive drugs
(angiotensin-converting enzyme inhibitors), and was found to
lead to substantial savings on health budgets [11]. However,
applying one reference price for all antihypertensive drugs
Table 5. Univariate Sensitivity Analyses
Assumptions Net Cost in Trial
a (US$) Cost-Effectiveness
in Trial
b (US$)
Main scenario 53,395 454
Software development not included 27,777 328
Salary for outreach visitors set to average pharmacist wage 68,782 530
Outreach visitors cover 0.5 practices per day
c 75,545 563
Outreach visitors cover two practices per day
c 43,873 407
Opportunity cost for physicians not included 44,664 411
Cost of thiazides set to the lowest thiazide price; cost of non-thiazides set to
highest non-thiazide price
51,500 454
Cost of thiazides set to highest thiazide price; cost non-thiazides set to lowest
non-thiazide price
94,557 454
Effect of intervention sustained for a second year (average net annual cost) 29,226 299
One potassium test for each additional patient started on a thiazide 54,157 458
aAll costs, including savings on drug costs.
bCost per additional patient started on a thiazide, rather than another antihypertensive drug, due to intervention.
cOne visit per day in main scenario.
DOI: 10.1371/journal.pmed.0030216.t005
Table 6. Costs Related to the Intervention in Model for Scaling Up to National Program
Item Total Costs in Study Population Costs per Practice
Natural Units Monetary
Units (US$)
Natural Units Monetary
Units (US$)
Software development 440 h 25,617 0.3 h 18
Training of outreach visitors 630 h 36,222 0.4 h 26
Printed materials 5,000 guidelines 40,853 3.5 guidelines 29
Travel costs 1,400 visits 305,706 1 visit 217
Salary of pharmacists doing outreach 7 full-time positions 713,458 7 h 506
Administration costs 1,200 h 39,674 0.9 h, office rent, overheads 28
Physician opportunity cost 1,760 h 174,610 1.2 h 124
Technical support 1,840 h 137,014 1.3 h 97
Potassium tests One test per extra thiazide user 15,245 2.9 tests 11
Drug costs (over 2 y)
a 9.3% absolute increase in proportion
of patients started on thiazides
3,012,395 9.3% absolute increase in proportion
of patients started on thiazides
2,137
Total (over 2 y) 1,523,996 1,081
a Drug costs in the second year were discounted by 4%.
DOI: 10.1371/journal.pmed.0030216.t006
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knowledge, been evaluated rigorously.
T h e r ei ss o m ed e b a t ea b o u tw h e t h e rt h ec h o i c eo f
antihypertensive drug has an impact on health outcomes,
which again may have economic implications. For some drug
classes, e.g., alpha-blocking agents [12], there is sound
evidence of inferiority compared to other classes, while for
other drug classes, e.g., angiotensin receptor blockers, it is
unclear whether the therapeutic effects are as good as for
other classes [13]. It could be argued that an increased use of
thiazides would lead to improved health outcomes [5], but the
superiority of thiazides over other drugs is small in any case,
and is not likely to have had much impact on the present
analysis.
There are weaknesses with our study, mainly related to the
many assumptions we had to make. However, almost all the
sensitivity analyses we conducted, including our suggested
best estimate, point in the same direction: if the intervention
effect is sustained for a second year, modest savings can be
expected.
We have assumed that the intervention had no impact on
the volume of prescribing of antihypertensive medication.
The trial data on prescribing volumes may be interpreted
differently since the absolute difference between prescribing
volumes in the experimental and control groups differed
between the baseline period (one year before the outreach
visit) and the study period (one year after the outreach visit)
(Table 3). However, the ratios of prescribing volumes during
the study period versus during the baseline period were
similar for the two groups, and the observed difference may
well be a chance ﬁnding. It is also highly unlikely that taking
this ﬁnding into account would change the conclusions.
This study is one of very few comprehensive economic
analyses of quality improvement strategies that include
educational outreach visits. The lack of economic evaluations
has been pointed out by others, and our ﬁndings illustrate
that such analyses are important for well-informed decision-
making.
Conclusions
The ﬁndings from our trial were similar to previous studies
of outreach visits aimed at inﬂuencing prescribing patterns.
Despite savings due to increased use of less expensive drugs,
the intervention resulted in a net cost within the 1 y that the
trial lasted. However, it is likely that the intervention would
lead to modest savings over a 2-y period.
Publicly funded educational outreach programs should
perhaps be targeted primarily at improving quality of care
rather than costs of health care, given the cost of outreach
visits, competition from drug companies, and the availability
of alternative strategies for controlling costs (such as
reference pricing, pre-authorization, and restrictions on
reimbursement).
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Editors’ Summary
Background. The importance of bridging the gap between research and
practice, and the need to improve the prescribing practices of family
doctors (general practitioners), is discussed in the Editors’ Summary for
an article related to this one (DOI: 10.1371/journal.pmed.0030134).
However, measures to improve prescribing practice can be expensive.
Economic evaluations are necessary to judge whether such measures are
worth the effort.
Doctors in a Norwegian study, described in the related article, were
encouraged to make more use of drugs belonging to the thiazide
‘‘family’’ to treat high blood pressure (hypertension). Thiazides are
cheaper than other antihypertensive drugs and in the average patient at
least as effective. Increasing their use should therefore save health
services money, but not reduce the effectiveness of the treatment of
hypertension. The study found that measures to actively encourage
doctors to follow prescribing guidelines did increase the use of thiazides,
but only by a small amount.
Why Was This Study Done? After having found that active promotion
of guidelines can make a difference, the researchers wanted to know
whether the cost of the efforts they made to encourage doctors to
follow the guidelines were justified by the savings made by increased
use of the cheaper drugs.
What Did the Researchers Do and Find? They calculated the money
saved where the prescribing guidelines were actively promoted, and
then worked out what this would amount to if the same were done in all
the family practices in Norway. They found that the cost of promoting
the guidelines was greater than the savings achieved during the course
of their study, which lasted one year. However, their calculations show
that after two years the money saved would have exceeded the costs.
After that, the savings would increase every year.
What Do These Findings Mean? As far as this particular example of
prescribing practice is concerned, although active promotion of guide-
lines increased costs in the short term, it will soon produce savings. This
will not always be the case; efforts to change prescribing practice may
sometimes involve the use of more effective but costlier drugs.
Improving the care of patients must always be the main aim, but
encouraging doctors to follow recommended guidelines on the
prescribing of drugs can sometimes reduce costs, too. These issues are
discussed further in a Perspective about this study (DOI: 10.1371/journal.
pmed.0030229).
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